Pineda-Gordillo A, Aguilar-Román AB, Reyes-Gómez U, Reyes-Hernández KL, Quero Hernández A, Arellano-Gómez KM

Language: Spanish
References: 21
Page: 86-90
PDF size: 143.86 Kb.

ABSTRACT

The frequency of malignant neoplasms in our country shows an increasing trend. Cancer in pediatrics is the second leading cause of death in children under 15 years of age. Infectious problems in cancer patients represent a serious issue, frequently linked to mortality. Common, opportunistic, and multidrug-resistant pathogens can cause diarrheal disease in children with cancer. Furthermore, diarrhea can be caused by the malignant neoplasm itself or as a side effect of chemotherapy and/or surgery. Timely intervention for diagnosis and the initiation of broad-spectrum antibiotic therapy are essential for a better prognosis.

REFERENCES

1. Cronin, K.A., Scott, S., Firth, A.U., Henley, S.J., Sherman,R.L., Siegel, R., Anderson, R.N., Kohler, B.A. et al., “Annualreport to the nation on the status of cáncer, parti: national cancer statistics”, Cáncer, 2018; 124 (13): 2785-2800.

2. Rivera, L.R., Cárdenas, C.R., Olaya, V.A., Shalkow, K.J.,Pérez, G.M. y Pérez, G.O., “El niño de población abiertacon cáncer en México. Consideraciones epidemiológicas”,An Med (México), 2015, 60 (2): 91-97.

3. Quero, H.A., Coronado, R., Pérez, B.A., Reyes, G.U. etal., “Neoplasias malignas en niños de dos hospitalesdel estado de Oaxaca”, Acta Pediatr Mex, 2006: 27 (4):183-189.

4. Tyler, L.V., Chee, Y.O., Dat, T., Jeffrey, T.J. y Gerstle, J.T.,“Gastrointestinal complications in children with acutemyeloid leukemia”, Leuk Lymphoma, 2010, 51: 768-777.

5. Krones, E. y Hogenauer, C., “Diarrea in the immunocompromisedpatient”, Gastroenterol Clin North Am, 2012,41 (3): 677-701.

6. Hadir, A.E., Nelly, H.A., Fatma, S., Maha, A.A. y Sherif,A.E., “Epidemiologic profile of symptomatic gastroenteritisin pediatric oncology patients receiving chemotherapy”,Pediatric Blood Cancer, 2004, 42 (4): 338-342.

7. Mohammad, N.M., Rodríguez, A., Zhengming, G.U.,Haiquing, Z., Li, T., Yilun, S. et al., “Epidemiology of diarrhealillness in pediatric oncology”, jpids, 2017, 6 (3):275-280.

8. Xe, X., Van, J.N., Muñoz, F.M., Revell, P.A., Korinetz, C.,Krance, R.A. et al., “Noroviruses as a cause of diarrheain immunocompromised pediatric hematopoietic stemcell and solid organ transplant”, Am J Transp, 2015, 15(7): 1874-1881.

9. Jiménez González, G.B., Martínez Gordillo, M.N., CaballeroSalazar S., Peralta Abarca, G.E., Cárdenas Cardoz,R., Arzate Barbosa, P. y Ponce Macotela, M., “Microsporidiosisen pacientes pediátricos con leucemia o linfoma”,Rev Invest Clin, 2012, 64 (1): 25-31.

10. Crews, J.D., Koo, H.L., Jiang, Z.D., Starke, J.R. y DuPont,H.L., “A hospital based study of the clinical characteristicsof Clostridium difficile infection in children”, PediatrInfect Dis, 2014, 33: 924-928.

11. Asencio, A., Di Bella, S., Lo Vecchio, A., Grau, S., Hart,W.M. e Isidoro, B., “The impact of Clostridium difficileinfection on resource use and costs in hospitals in painand Italy: a matched cohort study”, Int I Infect, 2015,36: 31-38.

12. Rizzatte, M., Brandalise, S.R., De Azevedo, A.C. y Pinheiro,V.R., “Neutropenic enterocolitis in children andyoung adults with cancer: prognostic value of clinicaland image findings”, Pediatr Hematol Oncol, 2010, 27:462-470.

13. Mullassery, D., Bader, A., Battersby, A.J., Mohammad,Z., Jones, E.L., Parmar, C. et al., “Diagnosis, incidence,and outcome of suspected typhlitis in oncology patients-experience in a tertiary pediatric surgical center inthe United Kingdom”, J Pediatr Surg, 2009, 44: 381-385.

14. Gray, J.W. y George, R.H., “Experience of vancomycin-resistant enterococci in a children’s hospital”, JHosp Infect, 2000, 45: 11-18.

15. Tuchmann, L. y Engelking, C., “Diarrea relacionada conel cáncer”, en Gates, R.A. y Fink, R.M. (eds.), Oncologynursing secrets, 2ª ed., Filadelfia, Hanley y Belfus, 2001,pp. 310-322.

16. Instituto Nacional del Cáncer, “Criterios comunes determinología para eventos adversos (ctcae)”, versión5.0, Bethesda, MD, Departamento de Salud y ServiciosHumanos de Estados Unidos, Institutos Nacionales dela Salud, 2017.

17. idsa, “Guidelines for the diagnosis and management ofinfectious diarrhea”, cid, 2017, 65 (15): 49.

18. Benson, A.B., Ajani, J.A., Catalano, R.B. et al., “Recommendedguidelines for the treatment of cancer treatment-induced diarrhea”, J Clin Oncol, 2004, 22 (14):2918-2926.

19. Johnston, B.C., Supina, A.L., Ospina, M. et al., “Probioticsfor the prevention of pediatric antibiotic-associateddiarrhea”, Cochrane database Syst Rev, 2007, (2):CD004827.

20. Cello, J.P., Grendell, J.H., Basuk, P. et al., “Effect of ocreotideon refractory aids-associated diarrhea. a prospective,multicenter clinical trial”, Ann Intern Med, 1991,115 (9): 705-710.

21. Zidan, J., Haim, N., Beny, A. et al., “Ocreotide in thetreatment of severe chemotherapy-induced diarrhea”,Ann Oncol, 2001, 12 (2): 227-229.